Rationally designed multitarget anticancer agents

Area of Science:

• Medicinal Chemistry
• Pharmacology
• Oncology

Background:

• Complex diseases like cancer often require targeting multiple pathways.
• Single molecules modulating multiple targets offer pharmacokinetic and pharmacodynamic advantages over drug combinations.
• Increasing drug resistance in cancer necessitates novel therapeutic strategies.

Purpose of the Study:

• To provide an overview of multitarget antitumor agents based on pharmacophore design.
• To highlight the design strategies for these agents, including pharmacophore combination and high-throughput screening.
• To emphasize the importance of validating these agents against multiple targets in various systems.

Main Methods:

• Review of reported multitarget antitumor agents.
• Analysis of agent design strategies focusing on pharmacophores.
• Examination of validation studies in cell-free systems, cancer cells, and resistant cell lines.

Main Results:

• Identified privileged pharmacophores like quinazoline, phenylaminopyrimidine, anthracycline, and naphthalimide in multitarget agent design.
• Demonstrated the effectiveness of these agents in both cell-free and cellular assays.
• Confirmed the potency of multitarget compounds against drug-resistant cancer cell lines.

Conclusions:

• Pharmacophore-based design is a viable strategy for developing multitarget antitumor agents.
• In-depth validation across multiple targets and models is crucial for assessing efficacy.
• Multitarget agents show significant promise in overcoming cancer drug resistance.